UPDATE: Goldman Sachs Raises Target to $36 on Thoratec

Goldman Sachs increases its price target to $36 on Neutral-rated Thoratec

as it updates sales and market penetration estimates on the company's model. Goldman Sachs says, "We are raising our numbers to reflect a 3Q2011 HeartWare launch (vs. 2Q2011 in our prior model). In addition, we are raising our penetration estimates given acceleration in market development initiatives." THOR closed at $33.59 a share yesterday.